The role of epidermal growth factor receptor tyrosine kinase inhibitors in the treatment of advanced stage non-small cell lung cancer

Journal of Thoracic Disease

Volumn 2, Issue 3, 2010, Pages 144-153

  Voon, Pei Jye ^a   Cho, Byoung Chul ^b   Yeo, Wee Lee ^a,c   Soo, Ross A ^a,c  

^a NATIONAL UNIVERSITY HEALTH SYSTEM   (Singapore)

^b Yonsei University College of Medicine   (South Korea)

^c NATIONAL UNIVERSITY OF SINGAPORE   (Singapore)

Author keywords

Epidermal growth factor receptor; Erlotinib; Gefitinib; Non small cell lung cancer; Tyrosine kinase inhibitors

Indexed keywords

EID: 84856928052     PISSN: 20721439     EISSN: 20776624     Source Type: Journal    
DOI: None     Document Type: Review

References (67)

1. NSCLC Meta-Analysis Collaborative Group. Chemotherapy in addition to supportive care improves survival in advanced non small cell lung cancer: a systemic review and meta-analysis of individual patient data from 16 randomized controlled trials. J Clin Oncol 2008;26:4617-25.
2. Ciardiello F, Tortora G. EGFR antagonists in cancer treatment. New Engl JMed 2008;358:1160-74.
3. Mendelsohn J, Baselga J. Status of epidermal growth receptor antagonists in the biology and treatment of cancer. J Clin Oncol 2003;21:2787-99.
4. Godin-Heymann N, Bryant I, Rivera M, Ulkus L, Bell D, Riese D, et al. Oncogenic activity of epidermal growth factor receptor kinase mutant alleles is enhanced by the T790M drug resistance mutation. Cancer Res 2007;67:7319-26.
5. Sharma S, Bell D, Settleman J, Haber D. Epidermal growth factor receptor mutations in lung cancer. Nat Rev Cancer 2007;7:169-81.
6. Ray M, Salgia R, Vokes E. The role of EGFR Inhibition in the treatment of Non-small cell lung Cancer. The Oncologist 2009;14:1116-30.
7. Giaccone G. HER1/EGFR-targeted agents: Predicting the future for patients with unpredictable outcomes to therapy. Ann Oncol 2005;16:538-48.
8. Lynch T, Bell D, Sordella R, Gurubhagavatula S, Okimoto R, Brannigan B, et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med 2004;350:2129-39.
9. Riely G, Pao W, Pham D, Li A, Rizvi N, Venkatraman E, et al. Clinical course of patients with non small cell lung cancer and epidermal growth factor receptor exon 19 and exon 21 mutations treated with gefitinib or erlotinib. Clin Cancer Res 2006;12:839-44.
10. Shigematsu H, Lin L, Takahashi T, Nomura M, Suzuki M, Wistuba I, et al. Clinical and biological features associated with epidermal growth factor receptor gene mutations in lung cancers. J Natl Cancer Inst 2005;97:339-46.
11. John T, Liu G, Tsao M. Overview of molecular testing in non-small-cell lung cancer: mutational analysis, gene copy number, protein expression and other biomarkers of EGFR for the prediction of response to tyrosine kinase inhibitors. Oncogene 2009;28:S14-23.
12. Fukuoka M, Yano S, Giaccone G, Tamura T, Nakagawa K, Douillard J, et al. Multi-institutional randomized phase II trial of gefitinib for previously treated patients with advanced non-small-cell lung cancer (The IDEAL 1 Trial) [corrected] J Clin Oncol 2003;21:2237-46. Erratum in: J Clin Oncol 2004;22:4811.
13. Kris M, Natale R, Herbst R, Lynch T, Prager D, Belani C, et al. Efficacy of gefitinib, an inhibitor of the epidermal growth factor receptor tyrosine kinase, in symptomatic patients with non-small cell lung cancer: a randomized trial. JAMA 2003;290:2149-58.
14. Cohen M, Williams G, Sridhara R, Chen G, Pazdur R. FDA drug approval summary: gefitinib (ZD1839) (Iressa) tablets. Oncologist 2003;8:303-6.
15. Shepherd F, Perira J, Ciuleanu T, Tan E, Hirsh V, Thongprasert S, et al. Erlotinib in previously treated non-small-cell lung cancer. N Engl J Med 2005;353:123-32.
16. Tsao M, Sakurada A, Cutz J, Zhu Q, Kamel-Reid S, Squire J, et al. Erlotinib in lung cancer - molecular and clinical predictors of outcome. N Engl J Med 2005;353:133-44.
17. Thatcher N, Chang A, Parikh P, Rodrigues Pereira J, Ciuleanu T, Von Pawel J, et al. Gefitinib plus best supportive care in previously treated patients with refractory advanced non-small-cell lung cancer: results from a randomised, placebo-controlled, multicentre study (Iressa Survival Evaluation in Lung Cancer). Lancet 2005;366:1527-37.
18. Kim E, Hirsh V, Mok T, Socinski M, Gervais R, Wu Y, et al. Gefitinib vs. docetaxel in previously treated non-small-cell lung cancer (INTEREST): a randomised phase III trial. Lancet 2008;372:1809-18.
19. Maruyama R, Nishiwaki Y, Tamura T, Yamamoto N, Tsuboi M, Nakagawa K, et al. Phase III study, V-15-32, of gefitinib vs. docetaxel in previously treated Japanese patients with non-small-cell lung cancer. J Clin Oncol2008;26:4244-52.
20. Lee D, Park K, Kim J, Lee J, Shin S, Kang J, et al. Randomized Phase III trial of gefitinib vs. docetaxel in non-small cell lung cancer patients who have previously received platinum-based chemotherapy. Clin Cancer Res 2010;16:1307-14.
21. Giaccone G, Herbst R, Manegold C, Scagliotti G, Rosell R, Miller V, et al. Gefitinib in combination with gemcitabine and cisplatin in advanced non-small-cell lung cancer: A phase III trial-INTACT 1. J Clin Oncol 2004;22:777-84.
22. Herbst R, Giaccone G, Schiller J, Reck M, Pereira J, Thomas M, et al. Gefitinib in combination with paclitaxel and carboplatin in advanced non-small-cell lung cancer: A phase III trial-INTACT 2. J Clin Oncol 2004;22:785-94.
23. Gatzemeier U, Pluzanska A, Szczesna A, Kaukel E, Roubec J, Rosa F, et al. Phase III study of erlotinib in combination with cisplatin and gemcitabine in advanced non-small-cell lung cancer: The Tarceva Lung Cancer Investigation Trial. J Clin Oncol 2007;25:1545-52.
24. Herbst R, Prager D, Hermann R, Fehrenbacher L, Johnson B, Sandler A, et al. TRIBUTE: A phase III trial of erlotinib HCl (OSI-774) combined with carboplatin and paclitaxel chemotherapy in advanced non small cell lung cancer. J Clin Oncol 2005;23:5892-9.
25. Mok T, Wu Y, Yu C, Zhou C, Chen Y, Zhang L, et al. Randomized, placebocontrolled, phase II study of sequential erlotinib and chemotherapy as first-line treatment for advanced non-small-cell lung cancer. J Clin Oncol 2009;27:5080-7.
26. 2010 A study of tarceva (erlotinib) or placebo in combination with platinumbased therapy as first line treatment in patients with advanced or recurrent non-small cell lung cancer [cited July 13]. Available from: http:// clinicaltrials.gov/ct2/show/NCT00883779. ClinicalTrials.gov registration number: NCT00883779.
27. Takeda K, Hida T, Sato T, Ando M, Seto T, Satouchi M, et al. Randomized phase III trial of platinum-doublet chemotherapy followed by gefitinib compared with continued platinum-doublet chemotherapy in Japanese patients with advanced non-small-cell lung cancer: results of a west Japan thoracic oncology group trial (WJTOG0203). J Clin Oncol 2010;28:753-60.
28. Cappuzzo F, Ciuleanu T, Stelmakh L, Cicenas S, Szczésna A, Juhász E, et al. Erlotinib as maintenance treatment in advanced non-small-cell lung cancer: a multicentre, randomised, placebo-controlled phase 3 study. Lancet Oncol 2010;11:521-9.
29. Mok T, Wu Y, Thongprasert S, Yang C, Chu D, Saijo N, et al. Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. N Engl J Med 2009;361:947-57.
30. Giaccone G, Gallegos R, Le Chevalier T, Thatcher N, Smit E, RodriguezJA, et al. Erlotinib for frontline treatment of advanced non-small cell lung cancer: a phase II study. Clin Cancer Res 2006;12:6049-55.
31. Akerley W, Boucher K, Bentz J, Arbogast K, Walters T. A phase II study of erlotinib as initial treatment for patients with stage IIIB-IV non-small cell lung cancer. J Thorac Oncol 2009;4:214-9.
32. 2010 TORCH: A study of tarceva or chemotherapy for the treatment of advanced non small cell lung cancer [cited July 7]. Available from: http://clinicaltrials.gov/ct2/show/NCT00349219. ClinicalTrials.gov registration number: NCT00349219.
33. Mitsudomi T, Morita S, Yatabe Y, Negoro S, Okamoto I, Tsurutani J, et al. West Japan Oncology Group. Gefitinib vs. cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trial. Lancet Oncol 2010;11:121-8.
34. Maemondo M, Inoue A, Kobayashi K, Sugawara S, Oizumi S, Isobe H, et al. Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR. N Engl J Med 2010;362:2380-8.
35. 2010 Available online at: http://www.ema.europa.eu/pdfs/human/press/ pr/27129209 en.pdf. Accessed July 7th,.
36. Lilenbaum R, Axelrod R, Thomas S, Dowlati A, Seigel L, Albert D, et al. Randomized phase II trial of erlotinib or standard chemotherapy in patients with advanced non-small-cell lung cancer and a performance status of 2. J Clin Oncol 2008;26:863-9.
37. Goss G, Ferry D, Wierzbicki R, Laurie SA, Thompson J, Biesma B, et al. Randomized phase II study of gefitinib compared with placebo in chemotherapy-naive patients with advanced non-small-cell lung cancer and poor performance status. J Clin Oncol 2009;27:2253-60.
38. Inoue A, Kobayashi K, Usui K, Maemondo M, Okinaga S, Mikami I, et al. First-line Gefitinib for patients with advanced non-small-cell lung cancer harboring epidermal growth factor receptor mutations without indication for chemotherapy. J Clin Oncol 2009;27:1394-00.
39. Lee S, Rudd R, Khan I, Upadhyay S, Lewanski CR, Falk S, et al. TOPICAL: Randomized phase III trial of erlotinib compared with placebo in chemotherapy-naive patients with advanced non-small cell lung cancer (NSCLC) and unsuitable for first-line chemotherapy [abstract]. J Clin Oncol 2010;28:s7504.
40. Herbst R, LoRusso P, Purdom M, Ward D. Dermatologic side effects associated with gefitinib therapy: clinical experience and management. Clin Lung Cancer 2003;4:366-9.
41. Perez-Soler R, Saltz L. Cutaneous adverse effects with HER1/EGFRtargeted agents: is there a silver lining? J Clin Oncol 2005;23:5235-46.
42. Inoue A, Saijo Y, Maemondo M, Gomi K, Tokue Y, Kimura Y, et al. Severe acute interstitial pneumonia and gefitinib. Lancet 2003;361:137-9.
43. Ando M, Okamoto I, Yamamoto N, Takeda K, Tamura K, Seto T, et al. Predictive factors for interstitial lung disease, antitumor response, and survival in non-small-cell lung cancer patients treated with gefitinib. J Clin Oncol 2006;24:2549-56.
44. Hammerman PS, Janne PA, Johnson BE. Resistance to epidermal growth factor receptor tyrosine kinase inhibitors in non-small cell lung cancer. Clin Cancer Res 2009;15:7502-9.
45. Kosaka T, Yatabe Y, Endoh H, Kuwano H, Takahashi T, Mitsudomi T, et al. Mutations of the epidermal growth factor receptor gene in lung cancer: Biological and clinical implications. Cancer Res 2004;64:8919-23.
46. Mitsudomi T, Steinberg S, Oie H, Mulshie J, Phelps R, Viallet J, et al. RAS gene mutations in non small cell lung cancers are associated with shortened survival irrespective of treatment intent. Cancer Res 1991;51:4999-5002.
47. Linardou H, Dahabreh I, Kanaloupiti D, Siannis F, Bafaloukos D, Kosmidis P, et al. Assessment of somatic KRAS mutations as a mechanism associated with resistance to EGFR targeted agents: A systematic review and metaanalysis of studies in advanced non-small-cell lung cancer and metastatic colorectal cancer. Lancet Oncol 2008;9:962-72.
48. Greulich H, Chen T, Feng W, Jänne P, Alvarez J, Zappaterra M, et al. Oncogenic transformation by inhibitor-sensitive and -resistant EGFR mutants. PLoS Med 2005;2:e313.
49. Kobayashi S, Boggon T, Dayaram T, Jänne P, Kocher O, Meyerson M, et al. EGFR mutation and resistance of non-small-cell lung cancer to gefitinib. N Engl J Med 2005;352:786-92.
50. Pao W, Miller VA, Politi KA, Riely G, Somwar R, Zakowski M, et al. Acquired resistance of lung adenocarcinomas to gefitinib or erlotinib is associated with a second mutation in the EGFR kinase domain. PLoS Med 2005;2:e73.
51. Inukai M, Toyooka S, Ito S, Asano H, Ichihara S, Soh J, et al. Presence of epidermal growth factor receptor gene T790M mutation as a minor clone in non-small cell lung cancer. Cancer Res 2006;66:7854-8.
52. Engelman J, Zejnullahu K, Mitsudomi T, Song Y, Hyland C, Park JO, et al. MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling. Science 2007;316:1039-43.
53. Yauch R, Januario T, Eberhard D, Cavet G, Zhu W, Fu L, et al. Epithelial vs. mesenchymal phenotype determines in vitro sensitivity and predicts clinical activity of erlotinib in lung cancer patients. Clin Cancer Res 2005;11:8686-98.
54. Tang J, He Q, Guo R, Chang X. Phosphorylated Akt overexpression and loss of PTEN expression in non-small cell lung cancer confers poor prognosis. Lung Cancer 2006;51:181-91.
55. Lim W, Zhang W, Miller C, Watters J, Gao F, Viswanathan A, et al. PTEN and phosphorylated AKT expression and prognosis in early- and late-stage non-small cell lung can cer. Oncol Rep 2007;17:853-7.
56. Morgillo F, Kim W, Kim E, Ciardello F, Hong W, Lee H, et al. Implication of the insulin-like growth factor-IR pathway in the resistance of nonsmall cell lung cancer cells to treatment with gefitinib. Clin Cancer Res 2007;13:2795-03.
57. Kwak E, Sordella R, Bell D, Heymann N, Okimoto R, Brannigan B, et al. Irreversible inhibitors of the EGF receptor may circumvent acquired resistance to gefitinib. Proc Natl Acad Sci U S A 2005;102:7665-70.
58. Li D, Ambrogio L, Shimamura T, Takahashi M, Chirieac LR, Padera R, et al. BIBW2992, an irreversible EGFR/ HER2 inhibitor highly effective in preclinical lung cancer models. Oncogene 2008;27:4702-11.
59. 2010 LUX lung 2 phase II single arm BIBW 2992 in NSCLC with EGFR activating mutations [cited July 16]. Available from: http:// clinicaltrials.gov/ct2/show/NCT00525148. ClinicalTrials.gov registration number: NCT00525148.
60. 2010 BIBW 2992 vs. chemotherapy as first line treatment in NSCLC with EGFRmutation [cited July 16]. Available from: http://www.clinicaltrials. gov/ct2/show/NCT00949650. ClinicalTrials.gov registration number: NCT00949650.
61. Sequist L, Besse B, Lynch T, Miller V, Wong K, Gitlitz B, et al. Neratinib, an irreversible pan-ErbB receptor tyrosine kinase inhibitor: results of a phase II trial in patients with advanced non-small-cell lung cancer. J Clin Oncol 2010;28:3076-83.
62. Janne PA, Reckamp K, Koczywas M, Camidge DR, Engelman JA, Khuri F, et al. A phase 2 trial of PF-00299804 (PF299), an oral irreversible HER tyrosine kinase inhibitor (TKI), in patients (pts) with advanced NSCLC after failure of prior chemotherapy and erlotinib: preliminary efficacy and safety results. J Thorac Oncol;4:S293-4.Abstr A3.1.
63. Yoshimura N, Kudoh S, Kimura T, Mitsuoka S, Matsuura K, Hirata K, et al. EKB-569, a new irreversible epidermal growth factor receptor tyrosine kinase inhibitor, with clinical activity in patients with non-small cell lung cancer with acquired resistance to gefitinib. Lung Cancer 2006;51:363-8.
64. De Boer R, Arrieta Ó, Gottfried M, Blackhall F, Yang C, Langmuir P, et al. Vandetanib plus pemetrexed vs. pemetrexed as second-line therapy in patients with advanced non small cell lung cancer (NSCLC): A randomized, double-blind phase III trial (ZEAL) [abstract]. J Clin Oncol 2009;27:8010.
65. Natale R, Thongprasert S, Greco F, Greco A, Thomas M, Tsai C, et al. Vandetanib vs. erlotinib in patients with advanced non-small cell lung cancer (NSCLC) after failure of at least one prior cytotoxic chemotherapy: A randomized, double-blind phase III trial (ZEST) [abstract]. J Clin Oncol 2009;27:8009.
66. Herbst R, Sun Y, Korfee S, Eberhadt W, Geermonpre P, Saijo N, et al. Vandetanib plus docetaxel vs. docetaxel as second-line treatment for patients with advanced non-small cell lung cancer (NSCLC): A randomized, double-blind phase III trial (ZODIAC). Lancet Oncol 2010;11:619-26.
67. Bahleda R, Soria J, Harbison C, Park J, Felip E, Hanna N, et al. Tumor regression and pharmacodynamic (PD) biomarker validation in non-small cell lung cancer (NSCLC) patients treated with the ErbB/VEGFR inhibitor BMS-690514 [abstract]. J Clin Oncol 2009;27:8098.